Developer docs
API playgroundTry for free, no card

Search company profiles

Graftys

Full company profile

uuid0003nv8

Namestring
Graftys
Websiteurl
graftys.com
Company typeenum
Private
Founded yearint
2005
Short descriptiontext

Graftys is a France-based medical device company founded in 2005 that develops injectable calcium phosphate bone cements and graft substitutes for orthopedic and bone-grafting procedures, serving hospitals, orthopedic clinics, and medical device distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJumet, Belgium
HQ citystring
Jumet
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
injectable bone cements, bone graft substitutes, calcium phosphate biomaterials, orthopedic biologics, bone regeneration products
Industry2 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Biomaterials
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biomaterial products
TypeOne Time License
Description

Revenue generated from the sale of injectable biomaterial products for bone grafting applications. The company is in a development phase with upcoming product launches planned for 2023 and 2024.

orthoworld.com
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Graftys develops and manufactures injectable biomaterials—specifically calcium phosphate bone cements and bone graft substitutes—for use in bone grafting and orthopedic surgical procedures. Its products are designed to enable minimally invasive bone regeneration procedures and are sold to hospitals, orthopedic clinics, and medical device distributors.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Calcium phosphate bone cements
CategoryOrthopedic Biomaterials
Description

Injectable calcium phosphate bone cements used in bone grafting and orthopedic procedures to support bone regeneration; sold to hospitals, orthopedic clinics, and medical device distributors.

2Bone graft substitutes
CategoryOrthopedic Biomaterials
Description

Injectable biomaterial bone graft substitutes designed to provide a minimally invasive alternative to traditional bone grafting, addressing limitations of autografts and donor site morbidity; intended for orthopedic and bone regeneration applications.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Biologics4Life
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Graftys acquired Biologics4Life in 2021 as a strategic move to enhance both sales capabilities and innovation capacity. This acquisition provided the company with additional resources to support its development of injectable biomaterials and upcoming product launches.

orthoworld.com
Peers10 records
TypeDirect peer
Description

Swedish orthobiologics company developing injectable bone graft substitutes (CERAMENT platform) for trauma and orthopedic applications. Closely comparable to Graftys in product format (injectable), indication focus, and minimally invasive bone regeneration strategy.

2Biomatlante
TypeDirect peer
Description

France-based developer of synthetic bone substitutes and calcium phosphate-based biomaterials. Direct geographic and technology overlap with Graftys in the calcium phosphate bone graft substitute category.

TypeDirect peer
Description

US-based company commercializing peptide-enhanced bone graft substitutes (i-FACTOR) for spinal fusion and orthopedic indications. Directly comparable in bone graft substitute product category and target surgical procedures.

TypeDirect peer
Description

German specialist in bone regeneration and dental biomaterials, offering synthetic bone graft substitutes and membranes. Comparable in product portfolio breadth across bone regeneration, including dental and orthopedic end-uses.

TypeDirect peer
Description

US-based manufacturer of bioactive synthetic bone graft substitutes (calcium phosphosilicate-based). Direct competitor in the synthetic bone graft substitute space with overlapping dental and orthopedic indications.

TypeDirect peer
Description

Swiss-headquartered leader in dental bone regeneration and matrix products (Bio-Oss, Bio-Gide). Comparable as a biomaterials specialist serving bone regeneration procedures, though more established and dental-focused.

TypeDirect peer
Description

US orthobiologics company focused on bone graft substitutes and spinal fixation-adjacent products. Comparable as a pure-play orthobiologics specialist of similar scale competing in the same bone graft substitute end-market.

TypeBroad incumbent
Description

Global medical device leader whose Spine division includes flagship bone graft substitutes such as INFUSE (rhBMP-2). Comparable as the dominant incumbent in the bone graft substitute market Graftys is targeting, with vastly larger sales infrastructure.

TypeBroad incumbent
Description

Orthopedic and surgical giant with a substantial orthobiologics portfolio (acquired Wright Medical, including bone graft substitutes). Competes broadly in the same end-procedural markets where Graftys' products are used.

TypeBroad incumbent
Description

Major orthopedic and trauma franchise offering synthetic and biologic bone graft solutions as part of its broader implant portfolio. Competes in the same trauma and reconstructive surgery channels as Graftys' bone graft substitutes.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Graftys

Orthopedic Biomaterialsgraftys.com

Graftys is a France-based medical device company founded in 2005 that develops injectable calcium phosphate bone cements and graft substitutes for orthopedic and bone-grafting procedures, serving hospitals, orthopedic clinics, and medical device distributors.

Graftys firmographics

Firmographics
Name
Graftys
Website
https://graftys.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
Graftys is a France-based medical device company founded in 2005 that develops injectable calcium phosphate bone cements and graft substitutes for orthopedic and bone-grafting procedures, serving hospitals, orthopedic clinics, and medical device distributors.
Ownership category
akta.pro rank

Graftys industry classification

Industry
Product category
Orthopedic Biomaterials
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Injectable bone cements
  • Bone graft substitutes
  • Calcium phosphate biomaterials
  • Orthopedic biologics
  • Bone regeneration products

Where Graftys is headquartered

Location

Headquarters

HQ city
Jumet
HQ country
Belgium
HQ region
Europe

Markets served

Graftys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Biomaterial products: Revenue generated from the sale of injectable biomaterial products for bone grafting applications. The company is in a development phase with upcoming product launches planned for 2023 and 2024.

Go-to-market motion1 record

Graftys product offering

Product offering

Core offering

Graftys develops and manufactures injectable biomaterials—specifically calcium phosphate bone cements and bone graft substitutes—for use in bone grafting and orthopedic surgical procedures. Its products are designed to enable minimally invasive bone regeneration procedures and are sold to hospitals, orthopedic clinics, and medical device distributors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Calcium phosphate bone cements Injectable calcium phosphate bone cements used in bone grafting and orthopedic procedures to support bone regeneration; sold to hospitals, orthopedic clinics, and medical device distributors.
  • Bone graft substitutes Injectable biomaterial bone graft substitutes designed to provide a minimally invasive alternative to traditional bone grafting, addressing limitations of autografts and donor site morbidity; intended for orthopedic and bone regeneration applications.

Companies that use Graftys

Customer profile

Segments1 record

Ideal customer profiles1 record

Graftys technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Graftys partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biologics4LifecoreStrategic or Co-development Partner · 1 January 2021Graftys acquired Biologics4Life in 2021 as a strategic move to enhance both sales capabilities and innovation capacity. This acquisition provided the company with additional resources to support its development of injectable biomaterials and upcoming product launches.

Scale indicators2 records

Graftys competitors and assessment

Company assessment

Direct peers

  • BoneSupport: Swedish orthobiologics company developing injectable bone graft substitutes (CERAMENT platform) for trauma and orthopedic applications. Closely comparable to Graftys in product format (injectable), indication focus, and minimally invasive bone regeneration strategy.
  • Biomatlante: France-based developer of synthetic bone substitutes and calcium phosphate-based biomaterials. Direct geographic and technology overlap with Graftys in the calcium phosphate bone graft substitute category.
  • Cerapedics: US-based company commercializing peptide-enhanced bone graft substitutes (i-FACTOR) for spinal fusion and orthopedic indications. Directly comparable in bone graft substitute product category and target surgical procedures.
  • Curasan: German specialist in bone regeneration and dental biomaterials, offering synthetic bone graft substitutes and membranes. Comparable in product portfolio breadth across bone regeneration, including dental and orthopedic end-uses.
  • NovaBone Products: US-based manufacturer of bioactive synthetic bone graft substitutes (calcium phosphosilicate-based). Direct competitor in the synthetic bone graft substitute space with overlapping dental and orthopedic indications.
  • Geistlich Pharma: Swiss-headquartered leader in dental bone regeneration and matrix products (Bio-Oss, Bio-Gide). Comparable as a biomaterials specialist serving bone regeneration procedures, though more established and dental-focused.
  • Xtant Medical: US orthobiologics company focused on bone graft substitutes and spinal fixation-adjacent products. Comparable as a pure-play orthobiologics specialist of similar scale competing in the same bone graft substitute end-market.

Broad incumbents

  • Medtronic (Spine & Biologics): Global medical device leader whose Spine division includes flagship bone graft substitutes such as INFUSE (rhBMP-2). Comparable as the dominant incumbent in the bone graft substitute market Graftys is targeting, with vastly larger sales infrastructure.
  • Stryker: Orthopedic and surgical giant with a substantial orthobiologics portfolio (acquired Wright Medical, including bone graft substitutes). Competes broadly in the same end-procedural markets where Graftys' products are used.
  • DePuy Synthes (Johnson & Johnson): Major orthopedic and trauma franchise offering synthetic and biologic bone graft solutions as part of its broader implant portfolio. Competes in the same trauma and reconstructive surgery channels as Graftys' bone graft substitutes.

Market position

Customer concentration

Graftys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Graftys leadership team

Management profile

Number of profiles

Profiles2 records

Graftys funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Graftys M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Graftys

What does Graftys do?

Graftys develops and manufactures injectable biomaterials—specifically calcium phosphate bone cements and bone graft substitutes—for use in bone grafting and orthopedic surgical procedures. Its products are designed to enable minimally invasive bone regeneration procedures and are sold to hospitals, orthopedic clinics, and medical device distributors.

When was Graftys founded?

Graftys was founded in 2005. It employs 11 to 50 people.

Where is Graftys based?

Graftys is headquartered in Jumet, Belgium, in the Europe region.

How does Graftys make money?

One revenue line is on record: biomaterial products.

Who are Graftys's main competitors?

Direct peers on record are BoneSupport, Biomatlante, Cerapedics, Curasan, NovaBone Products, Geistlich Pharma and Xtant Medical. Broad incumbents are Medtronic (Spine & Biologics), Stryker and DePuy Synthes (Johnson & Johnson).

Does Graftys have an API?

No public API is recorded for Graftys.

What industry is Graftys in?

Graftys's product category is Orthopedic Biomaterials. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals